- Home
- LTBR vs ALT Comparison
LTBR vs ALT Comparison
Compare LTBR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTBR | ALT |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 575.6M | 573.8M |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LTBR | ALT |
|---|---|---|
| Price | $6.28 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $17.11 |
| AVG Volume (30 Days) | 554.4K | ★ 3.1M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $6.22 | $2.56 |
| 52 Week High | $31.34 | $6.44 |
Technical Indicators
Market Signals| Indicator | LTBR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 34.73 |
| Support Level | N/A | $2.80 |
| Resistance Level | $7.04 | $3.35 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 6.10 | 3.28 |
Price Performance
Historical ComparisonAbout LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.